This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 12,268 
1 out of 159 
Years Active: 2025
Title: The Innovative Contributions of Hans-Henning Böhm
Introduction
Hans-Henning Böhm is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibody combinations for therapeutic applications. His work has the potential to impact cancer treatment and immunotherapy.
Latest Patents
Hans-Henning Böhm holds a patent for a pharmaceutical combination of anti-CEACAM6 and TIM3 antibodies. The patent describes combinations of at least two components, where component A is the anti-CEACAM6 antibody TPP-3310 and component B is an anti-TIM-3 antibody. The anti-TIM-3 antibodies mentioned include cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367, or INCAGN-2390. This innovative combination aims to enhance therapeutic efficacy in treating various conditions.
Career Highlights
Throughout his career, Hans-Henning Böhm has worked with prominent organizations such as Bayer Aktiengesellschaft and the Deutsches Krebsforschungszentrum. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Hans-Henning Böhm has collaborated with notable colleagues, including Jörg Willuda and Mark Trautwein. These partnerships have facilitated the exchange of ideas and expertise, further advancing the development of innovative therapies.
Conclusion
Hans-Henning Böhm's contributions to the field of pharmaceuticals, particularly through his patent on antibody combinations, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile